Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
RESMED INC shareholders approved Advisory vote on compensation of named executive officers (say-on-pay) at the 2022-11-16 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2022-11-16
Exact text from the filing
On November 16, 2022, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”). For Against Abstain Broker Non-Votes Item of business 1: Elect the following seven directors, each to serve until our 2023 annual meeting and until their successors are elected and qualified: Carol Burt 112,920,252 1,611,838 653,168 4,934,277 Jan De Witte 114,414,039 549,367 221,852 4,934,277 Karen Drexler 112,325,192 2,592,899 267,167 4,934,277 Michael Farrell 114,166,629 811,588 207,041 4,934,277 Peter Farrell 110,955,680 3,892,880 336,698 4,934,277 Harjit Gill 113,995,558 965,687 224,013 4,934,277 John Hernandez 113,649,577 1,311,352 224,329 4,934,277 Richard Sulpizio 102,238,286 12,686,008 260,
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
RESMED INC shareholders approved Ratification of selection of KPMG LLP as independent registered public accounting firm for fiscal year ending June 30, 2023 at the 2022-11-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2022-11-16
Exact text from the filing
On November 16, 2022, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”). For Against Abstain Broker Non-Votes Item of business 1: Elect the following seven directors, each to serve until our 2023 annual meeting and until their successors are elected and qualified: Carol Burt 112,920,252 1,611,838 653,168 4,934,277 Jan De Witte 114,414,039 549,367 221,852 4,934,277 Karen Drexler 112,325,192 2,592,899 267,167 4,934,277 Michael Farrell 114,166,629 811,588 207,041 4,934,277 Peter Farrell 110,955,680 3,892,880 336,698 4,934,277 Harjit Gill 113,995,558 965,687 224,013 4,934,277 John Hernandez 113,649,577 1,311,352 224,329 4,934,277 Richard Sulpizio 102,238,286 12,686,008 260,
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
RESMED INC shareholders approved Election of ten nominees to serve on the board of directors at the 2022-11-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2022-11-16
Exact text from the filing
On November 16, 2022, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”). For Against Abstain Broker Non-Votes Item of business 1: Elect the following seven directors, each to serve until our 2023 annual meeting and until their successors are elected and qualified: Carol Burt 112,920,252 1,611,838 653,168 4,934,277 Jan De Witte 114,414,039 549,367 221,852 4,934,277 Karen Drexler 112,325,192 2,592,899 267,167 4,934,277 Michael Farrell 114,166,629 811,588 207,041 4,934,277 Peter Farrell 110,955,680 3,892,880 336,698 4,934,277 Harjit Gill 113,995,558 965,687 224,013 4,934,277 John Hernandez 113,649,577 1,311,352 224,329 4,934,277 Richard Sulpizio 102,238,286 12,686,008 260,
View on SEC.gov